Cargando…

Curated human hyperbilirubinemia data and the respective OATP1B1 and 1B3 inhibition predictions

Hyperbilirubinemia is a pathological condition, very often indicative of underlying liver condition that is characterized by excessive accumulation of conjugated or unconjugated bilirubin in sinusoidal blood. In literature there are several indications associating the inhibition of the basolateral h...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kotsampasakou, Eleni, Escher, Sylvia E., Ecker, Gerhard F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2017
Materias:	Data Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5320065/ https://www.ncbi.nlm.nih.gov/pubmed/28243614 http://dx.doi.org/10.1016/j.dib.2017.02.009

Ejemplares similares

Identification of Novel Inhibitors of Organic Anion Transporting Polypeptides 1B1 and 1B3 (OATP1B1 and OATP1B3) Using a Consensus Vote of Six Classification Models
por: Kotsampasakou, Eleni, et al.
Publicado: (2015)

Predicting drug-induced liver injury: The importance of data curation
por: Kotsampasakou, Eleni, et al.
Publicado: (2017)

Structure of human drug transporters OATP1B1 and OATP1B3
por: Ciută, Anca-Denise, et al.
Publicado: (2023)

Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1
por: Nies, Anne T, et al.
Publicado: (2013)

Differential Preincubation Effects of Nicardipine on OATP1B1- and OATP1B3-Mediated Transport in the Presence and Absence of Protein: Implications in Assessing OATP1B1- and OATP1B3-Mediated Drug–Drug Interactions
por: Kayesh, Ruhul, et al.
Publicado: (2023)

PBPK Modeling of Coproporphyrin I as an Endogenous Biomarker for Drug Interactions Involving Inhibition of Hepatic OATP1B1 and OATP1B3
por: Yoshikado, Takashi, et al.
Publicado: (2018)

Transcriptional Regulation of Liver-Type OATP1B3 (Lt-OATP1B3) and Cancer-Type OATP1B3 (Ct-OATP1B3) Studied in Hepatocyte-Derived and Colon Cancer-Derived Cell Lines
por: Haberkorn, Bastian, et al.
Publicado: (2023)

Dose‐Dependent Inhibition of OATP1B by Rifampicin in Healthy Volunteers: Comprehensive Evaluation of Candidate Biomarkers and OATP1B Probe Drugs
por: Mori, Daiki, et al.
Publicado: (2020)

Selectivity and Potency of Microcystin Congeners against OATP1B1 and OATP1B3 Expressing Cancer Cells
por: Niedermeyer, Timo H. J., et al.
Publicado: (2014)

Role of OATP1B1 and OATP1B3 in Drug-Drug Interactions Mediated by Tyrosine Kinase Inhibitors
por: Garrison, Dominique A., et al.
Publicado: (2020)

Comparing the performance of meta-classifiers—a case study on selected imbalanced data sets relevant for prediction of liver toxicity
por: Jain, Sankalp, et al.
Publicado: (2018)

Predicting Drug-Induced Cholestasis with the Help of Hepatic Transporters—An in Silico Modeling Approach
por: Kotsampasakou, Eleni, et al.
Publicado: (2017)

OATP1B1 and tumour OATP1B3 modulate exposure, toxicity, and survival after irinotecan-based chemotherapy
por: Teft, W A, et al.
Publicado: (2015)

Preference of Conjugated Bile Acids over Unconjugated Bile Acids as Substrates for OATP1B1 and OATP1B3
por: Suga, Takahiro, et al.
Publicado: (2017)

Using a competitive counterflow assay to identify novel cationic substrates of OATP1B1 and OATP1B3
por: Schnegelberger, Regina D., et al.
Publicado: (2022)

Regulation of Organic Anion Transporting Polypeptides (OATP) 1B1- and OATP1B3-Mediated Transport: An Updated Review in the Context of OATP-Mediated Drug-Drug Interactions
por: Alam, Khondoker, et al.
Publicado: (2018)

Effect of Rifampin‐Mediated OATP1B1 and OATP1B3 Transporter Inhibition on the Pharmacokinetics of the P2Y12 Receptor Antagonist Selatogrel
por: Schilling, Uta, et al.
Publicado: (2020)

Variability in In Vitro OATP1B1/1B3 Inhibition Data: Impact of Incubation Conditions on Variability and Subsequent Drug Interaction Predictions
por: McFeely, Savannah J., et al.
Publicado: (2019)

Organic anion transporting polypeptides OATP1B1 and OATP1B3 and their genetic variants influence the pharmacokinetics and pharmacodynamics of raloxifene
por: Trdan Lušin, Tina, et al.
Publicado: (2012)

Montelukast Disposition: No Indication of Transporter-Mediated Uptake in OATP2B1 and OATP1B1 Expressing HEK293 Cells
por: Brännström, Marie, et al.
Publicado: (2015)

Inhibition of OATP1B1 by tyrosine kinase inhibitors: in vitro–in vivo correlations
por: Hu, S, et al.
Publicado: (2014)

Inhibition of OATP1B1 by tyrosine kinase inhibitors: in vitro-in vivo correlations
por: Hu, S, et al.
Publicado: (2017)

Toward Prospective Prediction of Pharmacokinetics in OATP1B1 Genetic Variant Populations
por: Li, R, et al.
Publicado: (2014)

Influence of OATP1B1 and OATP1B3 mutations and glomerular filtration rate on trough serum digoxin concentration in the Chinese population: A prospective cohort study
por: Chen, Shu-qing, et al.
Publicado: (2019)

Results From Drug–Drug Interaction Studies In Vitro and In Vivo Investigating the Inhibitory Effect of Finerenone on the Drug Transporters BCRP, OATP1B1, and OATP1B3
por: Heinig, Roland, et al.
Publicado: (2022)

Risk of Developing Hepatocellular Carcinoma following Depressive Disorder Based on the Expression Level of Oatp2a1 and Oatp2b1
por: Chen, Yan, et al.
Publicado: (2019)

Inhibitory Effects of Green Tea and (–)-Epigallocatechin Gallate on Transport by OATP1B1, OATP1B3, OCT1, OCT2, MATE1, MATE2-K and P-Glycoprotein
por: Knop, Jana, et al.
Publicado: (2015)

Influence of OATP1B1 Function on the Disposition of Sorafenib‐β‐D‐Glucuronide
por: Bins, S, et al.
Publicado: (2017)

3012 Functional consequences of pravastatin isomerization on OATP1B1-mediated transport
por: Wagner, Jonathan, et al.
Publicado: (2019)

Performance of Plasma Coproporphyrin I and III as OATP1B1 Biomarkers in Humans
por: Neuvonen, Mikko, et al.
Publicado: (2021)

In Vitro and In Silico Strategies to Identify OATP1B1 Inhibitors and Predict Clinical Drug–Drug Interactions
por: Karlgren, Maria, et al.
Publicado: (2011)

Flavopiridol Pharmacogenetics: Clinical and Functional Evidence for the Role of SLCO1B1/OATP1B1 in Flavopiridol Disposition
por: Ni, Wenjun, et al.
Publicado: (2010)

Polymorphic variants of SLCO1B1 in neonatal hyperbilirubinemia in China
por: Liu, Jiebo, et al.
Publicado: (2013)

Commentary on: “Influence of OATP1B1 Function on the Disposition of Sorafenib‐β‐D‐Glucuronide”
por: Morrissey, KM, et al.
Publicado: (2017)

The Effect of Single Nucleotide Variations in the Transmembrane Domain of OATP1B1 on in vitro Functionality
por: Kiander, Wilma, et al.
Publicado: (2021)

Quantification of OATP1B1 endogenous metabolites coproporphyrin I and III in human urine
por: Jang, Yeonseo, et al.
Publicado: (2023)

Application of a Physiologically Based Pharmacokinetic Model to Predict OATP1B1-Related Variability in Pharmacodynamics of Rosuvastatin
por: Rose, R H, et al.
Publicado: (2014)

Association of CYP2D6*10, OATP1B1 A388G, and OATP1B1 T521C Polymorphisms and Overall Survival of Breast Cancer Patients after Tamoxifen Therapy
por: Zhang, Xuefeng, et al.
Publicado: (2015)

Introduction of Aromatic Ring-Containing Substituents in Cyclic Nucleotides Is Associated with Inhibition of Toxin Uptake by the Hepatocyte Transporters OATP 1B1 and 1B3
por: Herfindal, Lars, et al.
Publicado: (2014)

Mechanistic in vitro studies indicate that the clinical drug–drug interactions between protease inhibitors and rosuvastatin are driven by inhibition of intestinal BCRP and hepatic OATP1B1 with minimal contribution from OATP1B3, NTCP and OAT3
por: Elsby, Robert, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3t0s1qnl938ksq0b2ko9stalv2